Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2020
Premiums & Annuity Revenue	413.7	370.6	315.2	172.4	77	77.3	Upgrade
Total Interest & Dividend Income	37.2	34	24.7	8.4	1.9	1.5	Upgrade
Other Revenue	149.8	121.9	89.9	75.9	49.5	15.6	Upgrade
Total Revenue	600.7	526.5	429.8	256.7	128.4	94.4	Upgrade
Revenue Growth (YoY)	27.51%	22.50%	67.43%	99.92%	36.02%	40.27%	Upgrade
Policy Benefits	303.5	277	280.4	167.3	71.9	54.7	Upgrade
Selling, General & Administrative	436.2	384.8	315	319.2	247.5	150.3	Upgrade
Total Operating Expenses	802.1	724.2	652.5	543.1	362	215.2	Upgrade
Operating Income	-201.4	-197.7	-222.7	-286.4	-233.6	-120.8	Upgrade
Interest Expense	-6.2	-6.2	-0.4	-	-	-	Upgrade
EBT Excluding Unusual Items	-207.6	-203.9	-223.1	-286.4	-233.6	-120.8	Upgrade
Merger & Restructuring Charges	-	-	-	-8.4	-	-	Upgrade
Asset Writedown	-	-	-3.7	-	-	-	Upgrade
Legal Settlements	-	-	-3	-	-	-	Upgrade
Pretax Income	-207.6	-203.9	-229.8	-294.8	-233.6	-120.8	Upgrade
Income Tax Expense	-3.6	-1.7	7.1	3	7.7	1.5	Upgrade
Net Income	-204	-202.2	-236.9	-297.8	-241.3	-122.3	Upgrade
Net Income to Common	-204	-202.2	-236.9	-297.8	-241.3	-122.3	Upgrade
Shares Outstanding (Basic)	72	71	70	65	61	34	Upgrade
Shares Outstanding (Diluted)	72	71	70	65	61	34	Upgrade
Shares Change (YoY)	3.09%	1.96%	7.30%	6.04%	81.92%	202.53%	Upgrade
EPS (Basic)	-2.82	-2.85	-3.40	-4.59	-3.94	-3.63	Upgrade
EPS (Diluted)	-2.82	-2.85	-3.40	-4.59	-3.94	-3.63	Upgrade
Free Cash Flow	-21.4	-20.8	-128.3	-173.1	-154	-96.1	Upgrade
Free Cash Flow Per Share	-0.30	-0.29	-1.84	-2.67	-2.52	-2.85	Upgrade
Operating Margin	-33.53%	-37.55%	-51.81%	-111.57%	-181.93%	-127.97%	Upgrade
Profit Margin	-33.96%	-38.41%	-55.12%	-116.01%	-187.93%	-129.56%	Upgrade
Free Cash Flow Margin	-3.56%	-3.95%	-29.85%	-67.43%	-119.94%	-101.80%	Upgrade
EBITDA	-182.4	-177.7	-202.7	-274.2	-229.9	-119.1	Upgrade
EBITDA Margin	-30.36%	-33.75%	-47.16%	-106.82%	-179.05%	-126.16%	Upgrade
D&A For EBITDA	19	20	20	12.2	3.7	1.7	Upgrade
EBIT	-201.4	-197.7	-222.7	-286.4	-233.6	-120.8	Upgrade
EBIT Margin	-33.53%	-37.55%	-51.81%	-111.57%	-181.93%	-127.97%	Upgrade
Revenue as Reported	600.7	526.5	429.8	256.7	128.4	94.4	Upgrade

Updated May 6, 2025. Source: S&P Global Market Intelligence. Insurance template. Financial Sources.

SEC Filings: 10-K · 10-Q